Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

ry movements was shown across multiple assessment points. After the seven-day washout period most patients' AIMS scores returned to their baseline levels. The adverse events reported during administration of study drug were transient and mild or moderate including one subject with dizziness and one with restlessness. One subject became anxious and agitated seven days after stopping the study medication due to return of baseline-intensity dyskinesia.

About the Abnormal Involuntary Movement Scale (AIMS)

The AIMS was developed in 1976, and has been used extensively in movement disorder assessments. It consists of ten distinct ratings that are observed both spontaneously and upon activation. Ratings one through seven score facial, extremity and trunk movements; items eight through ten are overall global judgments of severity, incapacitation and patient awareness. All ten ratings are scored on a zero to four scale with zero being rated as none, and four being rated as severe.

About NBI-98854

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects. NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may well be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and Tardive Dystonia.

Next Steps for NBI-98854

All of the clinical work to date for NBI-98854 has been conducted in Canada. The Company plans to open an IND
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... TRIANGLE PARK, N.C. , May 1, 2015  United ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer of ... company,s business at the Deutsche Bank 40 th Annual ... The presentation will take place on Wednesday, May ... accessed via a live webcast on the United Therapeutics website ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015   ... drugs, announced today an update on its Ebola antiviral ... of Tamir,s leading candidates, TMR004, is currently being evaluated ... frontline of the battle against Ebola. During the first ... Voice And Leadership Meeting To Accelerate The Evaluation of ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology ... capacity and production capability to serve biotechnology pharmaceutical ... service fulfillment continues to drive Nitto Avecia to ... capacities. , In Fall 2014, Nitto ... equipment at its Milford, MA facility, which is ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Biodata, ... notebook with integrated protocols and specimen management systems, ... solutions and consulting services for life science research, ... of Labguru’s newest feature: chemical structure and reaction ... features for biologists, bio-chemists, and more, the integration ...
Breaking Biology Technology:Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Free access to 'Best Practices for Long-term ... R. Rajagopal's highly successful November 2007 position ... Option', is being offered. It emphasizes the ... as it nears commercialization as a viable ...
... Relocation to California, MELBOURNE, Australia, July 10 ... Dr. Devron Averett as Chief Scientific,Advisor to the ... will work closely with the,company,s executive management team, ... scientific leadership and guidance. He has held global,leadership ...
... Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced that the ... passed by the U.S. House of,Representatives on June 24, ... would,continue the 2007 reimbursement methodology for therapeutic,radioimmunotherapies for an ... 2008. In December, Congress froze reimbursement rates at the ...
Cached Biology Technology:Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist 2Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 2Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 3Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 4
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... 2, 2015 At its 2015 ACMG Annual ... , the American College of Medical Genetics and ... to its Board.  Members of the ACMG Board of ... forming and advancing its policies and programs. ACMG is ... "It,s an eventful time in medical genetics and ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Since Edison,s first bulb, heat has been a mostly undesirable ... light into heat at the point of need, on the ... The method created by the Rice labs of Michael Wong, ... American Chemical Society journal ACS Nano makes use ...
... Panama provides an unprecedented level of detail regarding the ... to the forest canopy. Yves Basset, scientific coordinator of ... Institute, led an international team on Project IBISCA-Panama to ... hectare forest hosts a total of around 25,000 arthropod ...
... discovered a "two-faced" group of cells at work in ... or promote tumor growth. These cells are a subset ... in healthy individuals In this previously unknown Treg ... shown to differentiate between cancer-protecting and cancer-promoting properties. ...
Cached Biology News:Rice uses light to remotely trigger biochemical reactions 2Rice uses light to remotely trigger biochemical reactions 3Rice uses light to remotely trigger biochemical reactions 4More bang for bugs 2'Two-faced' cells discovered in colon cancer 2
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
...
Homo sapiens MEP50 protein, mRNA...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: